Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pharmanet Names Dr. George Scott Vice President of Bioanalytical Services

Published: Friday, July 22, 2011
Last Updated: Friday, July 22, 2011
Bookmark and Share
Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada.

PharmaNet Development Group, Inc., has announced that it has appointed George Scott, PhD, as Vice President, Bioanalytical Services.

In this role, Dr. Scott will provide leadership for PharmaNet's GLP-compliant bioanalytical laboratories in the United States and Canada.

In addition, he will build upon PharmaNet's bioanalytical method development, validation and sample analysis services across the continuum of drug development and lead PharmaNet's geographical and service expansion strategies in bioanalysis.

"Dr. Scott has a very impressive scientific and operational experience base in bioanalysis," commented Riaz Bandali, President, Early Stage Development. "He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen."

Prior to joining PharmaNet, Dr. Scott served as Director of Pharmacokinetics and Drug Metabolism at Amgen, a world leader in biotechnology. He was responsible for overseeing the immunochemistry and small molecule bioanalytical capabilities.

He was also integrally involved in the Amgen Leadership Committee that managed strategic outsourcing decisions for small molecule and large molecule programs to global bioanalytical service providers.

Prior to Amgen, Dr. Scott was responsible for establishing and growing the global ligand binding services at another CRO.

Dr. Scott holds a Bachelors of Science in Neuroscience from Edinburgh University and was awarded a PhD from the University of Nottingham for studies in neuropharmacology.

After four years in post-doctoral positions at Dalhousie University and the University of Montreal, he served for two years as an Assistant Professor in the faculty of Dentistry at McGill University.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PharmaNet’s Bioanalytical Laboratory Recognized by the Standards Council of Canada for Good Laboratory Practice Compliance
OECD GLP recognition consolidates Company’s position as the partner of choice for companies seeking assured international registration of their products.
Wednesday, June 29, 2011
Valerie Palumbo Joins Pharmanet as Senior Vice President, Corporate Quality Assurance
Ms. Palumbo has more than twenty years of experience in the development and implementation of quality assurance programs in the FDA-regulated drug and medical device industries.
Tuesday, May 03, 2011
Pharmanet Appoint New Chief Medical Officer
PharmaNet Development Group, Inc. announces that Jeffrey Freitag, M.D., Senior Vice President, PharmaNet Consulting, will expand his role to become Chief Medical Officer of PharmaNet.
Monday, February 21, 2011
PharmaNet Launches New Brand Identity
PharmaNet Development Group, Inc. announced that it is launching a new brand identity and tagline, “PharmaNet Works For You”. The new brand and tagline reflect the Company’s promise to its clients to provide intelligent solutions to accelerate drug development programs consistent with the highest standards of regulatory compliance, quality and reliability.
Thursday, November 25, 2010
PharmaNet Development Group Collaborates with Abacus International
Collaboration is aimed to support patient registries and health economic programs in Europe.
Monday, July 26, 2010
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
‘Cellbots’ Chase Down Cancer, Deliver Drugs Directly to Tumors
Programmable T cells shown to be versatile, precise, and powerful in lab studies.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!